COVID 2020 versus COVID 2021-A Data Base Research

Abstract

Aim: Purpose of the research was to find out data base comparisons between covidsituation in 2020 versus the change of situation in 2021 Methodology: A search was done, in WoS (SCI, SSCI, A&HCI and ESCI) and Scopus, to any documents published in the past 1 year (Jan 30, 2020 to April 30, 2020) using the search query “SARS-CoV-2” OR “COVID-19” OR “Coronavirus 2019” OR “Corona Virus 2019” OR “novel coronavirus” OR “novel corona virus” OR “2019-nCoV”, in titles and keywords. Data from Clarivate Analytics’ Web of Science, and Elsevier’s Scopus, which do not index preprints, were assessed. With final count of 53 peer reviewed research, the data was collected and then subjected to descriptive statistical analysis using SPSS 25.0. Results: In all the cases from 2020, it was evident that around 63.5% had treatment schedule consisting of HCQ and Ivermectin (32.1%) as well as plasmapheresis (27.4%). In 2021, 56.9% had remdesivir as the major treatment along with humidified oxygen (88.3%). Amount of HRCT chest also increased as compared to 2020, from 39.8% to a staggering 84.6% in 2021. Britain variant was detected in almost 12 peer review research, 1 peer review had cases related to south African variant, 3 with Brazilian variant and 1 for double mutant detected in India. Conclusion: A paradigm shift has been seen in situation from 2020, be it vaccines, Remdesivir, increased usage of HRCT, mutations in viral structure, or post covid infections with glucocorticoid usage, in the year 2021 for coronavirus situation worldwide.